|Article||Equity||Entry Price||Peak Price||Gain/Loss||12/31/2018|
MS 2018 performance record represents the potential investors could have made if they bought at the time we initiated coverage of the equity with a buy rating. This total comes to 371% from August 17th to December 31st, 2018.
Click here to Unlock Premium and #Join our trading team.
The above equities did not move because of our articles. Rather either our thesis played out, or the stock recovered from an overreaction by the market. In some instances, if the investor held onto their position too long or past a point we argued exposed an investor to too much risk there is a strong possibility they lost money. In the case of CNAT, we wrote an article arguing for a price run-up into the data release. In that article, we noted that we would not hold through the data release due to high risks. In another CNAT article, we laid out the upside if ENCORE-PH met its primary endpoint but did not advocate for buying/holding through the readout. We strongly advocate for taking healthy profits rather than holding out for higher returns. Making a profit is always better than losing money. If an investor held their position too long past a PDUFA date (such as with ACRX or CPRX) then there is a good chance they could have lost money or broke even. Remember, we don’t marry stocks we only date them. And the length of the respective relationships is contingent upon but not limited to company fundamentals, risk factors, material developments, and market conditions. MS articles are never a directive to invest. Rather our articles are meant to serve as informative, evidence comprised information for an investor to use in conducting their due diligence research.
Now that 2018 is behind us it is time to look ahead to 2019 and beyond!
As always, let’s get it!!!
MS Money Move and its Chief Operating Officer who is a scientist and individual investor, as well as its affiliates are not registered financial advisors. Our posts should serve as educational material to help you conduct due diligence research. Posts and articles are not directives or recommendations to invest in any security. We reserve the right to buy or sell any security for ourselves without any notification except when required by law. We are not responsible for the action of our affiliates. Investment theses may change due to the variable nature of the securities market. Because of this there is great risk when investing in stocks and options which can result is capital loss. Additionally, past performance by MS Money Moves or any security is not a predictor of future performance. Everyone should conduct their own research and due diligence before making an investment decision. We recommend you consult a financial advisor regarding any investment action.
The biotech sector is especially volatile. Stock prices may fluctuate substantially based on material or nonmaterial developments. We encourage everyone to familiarize themselves with clinical trial processes, relevant terminology, FDA/SEC rules and regulations, and the general processes of drug & therapy development/approval. Always do independent research in a security prior to investing.